Browse

The new edition of this resource summarizes essential information on all the major drugs currently used in clinical psychiatric practice via a discussion on drugs in psychiatry, the principles of psychopharmacology, and the foundation of the sound, scientifically based use of drugs in psychiatry.Less

This resource summarizes the several promising new avenues for the development of future drugs for the treatment of migraine, including cortical-spreading depression inhibition, nitric oxide synthase inhibition and calcitonin gene-related peptide (CGRP) receptor antagonism, as well as other potential targets, and presents frontline knowledge of these evolving modalities as far as it is available in the public domain.Less

Opioids in Non-Cancer Pain brings clinicians up to date on the current use of opioid drugs in patients with non-cancer pain, and highlights the potential benefits of therapy as well as the problems that can occur.Less

Phase I trials are a critical first step in the study of novel cancer therapeutic approaches. Their primary goals are to identify the recommended dose, schedule and pharmacologic behavior of new agents or new combinations of agents and to describe the adverse effects of treatment. In cancer therapeutics, such studies have particular challenges. Due to the nature of the effects of treatment, most such studies are conducted in patients with advanced malignancy, rather than in healthy volunteers. Furthermore, the endpoints of these trials are usually measures adverse effects rather than molecular target or anti-tumor effects. These factors render the design, conduct, analysis and ethical aspects of phase I cancer trials unique. As the only comprehensive book on this topic, this online resource for oncology trainees and specialists explains cancer drug development and includes information on Phase 0 Trials, immunotherapeutics, and updated information on the process, pitfalls, and logistics of Phase I Trials.Less